TNF Pharmaceuticals, Inc.
855 N. Wolfe Street, Suite 623
Baltimore, MD 21205
August 9, 2024
| VIA EDGAR | ||
| Division of Corporation Finance | ||
| Office of Life Sciences | ||
| U.S. Securities and Exchange Commission | ||
| Washington, D.C. 20549 | ||
| Attention: | Tamika Sheppard | |
| Re: | TNF Pharmaceuticals, Inc. (f/k/a MyMD Pharmaceuticals, Inc.) Registration Statement on Form S-3 Originally filed on June 21, 2024, as amended on August 8, 2024 File No. 333-280415 (as amended, the “Registration Statement”) Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, TNF Pharmaceuticals, Inc., formally known as MyMD Pharmaceuticals, Inc. (the “Company”), hereby respectfully requests acceleration of the effective date of the Registration Statement, so that it may become effective at 4:30 p.m., Eastern Time, on August 12, 2024, or as soon thereafter as practicable.
Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Alla Digilova, Esq. at (212) 659-4993.
| Very truly yours, | ||
| TNF Pharmaceuticals, Inc. | ||
| By: | /s/ Joshua Silverman | |
| Joshua Silverman | ||
| Chaiman of the Board | ||
| cc: | Alla Digilova, Esq., Haynes and Boone, LLP |